Isis pharmaceuticals stanozolol

Nadya Mikdashi, a Lebanese addiction specialist who runs Skoun , Lebanon’s only outpatient treatment center, was not surprised to hear that soldiers on all sides of Syria’s conflict have turned to amphetamines. “Historically, fighters always used drugs,” she says. “Since the beginning of availability of synthetic drugs as well, you know, this has been going on.” Only a few patients in her facility have come in contact with Captagon, but Mikdashi is worried by the recent reports of shipments from Syria being intercepted by authorities from Dubai to the West Bank. “Where are these drugs going? To the Gulf, to Sudan, to different places.…A lot of people in the region are using amphetamines.”

The . patent office has awarded Mike Adams patent NO. US 9526751 B2 for the invention of “ Cesium Eliminator ,” a lifesaving invention that removes up to 95% of radioactive cesium from the human digestive tract. Adams has pledged to donate full patent licensing rights to any state or national government that needs to manufacture the product to save human lives in the aftermath of a nuclear accident, disaster, act of war or act of terrorism. He has also stockpiled 10,000 kg of raw material to manufacture Cesium Eliminator in a Texas warehouse, and plans to donate the finished product to help save lives in Texas when the next nuclear event occurs. No independent scientist in the world has done more research on the removal of radioactive elements from the human digestive tract.

This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of inotersen and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2016 , and its most recent quarterly report on Form 10-Q, which are on file with the SEC . Copies of these and other documents are available from the Company.

Isis pharmaceuticals stanozolol

isis pharmaceuticals stanozolol


isis pharmaceuticals stanozololisis pharmaceuticals stanozololisis pharmaceuticals stanozololisis pharmaceuticals stanozololisis pharmaceuticals stanozolol